BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial

Journal: Nature Medicine

Published: 2020-05-25

DOI: 10.1038/s41591-020-0880-x

Affiliations: 27

Authors: 26

Go to article
Institutions Share
BioLineRx Ltd., Israel 0.19
Tel Aviv University (TAU), Israel 0.06
Samsung Medical Center (SMC), South Korea 0.04
Hadassah Medical Center, HUJI, Israel 0.04
University Hospital of Fuenlabrada, Spain 0.04
Ochsner Health System, United States of America (USA) 0.04
Harvard University, United States of America (USA) 0.04
Washington University in St. Louis (WUSTL), United States of America (USA) 0.04
Mayo Clinic, United States of America (USA) 0.04
Merck & Co., Inc., United States of America (USA) 0.04
Investigación Sanitaria del Hospital Gregorio Marañón (IISGM), Spain 0.04
StatExcellence Ltd., Israel 0.04
The Translational Genomics Research Institute (TGen), United States of America (USA) 0.04
HonorHealth Research Institute, United States of America (USA) 0.04
Vall d'Hebron University Hospital (HUVH), ICS, Spain 0.04
Rambam Health Care Campus (RambamHCC), IIT, Israel 0.04
University of Navarra (UNAV), Spain 0.04
Cornell University, United States of America (USA) 0.02
Beth Israel Deaconess Medical Center (BIDMC), United States of America (USA) 0.02
Biomedical Research Networking Centers (CIBER), Spain 0.02
Hospital La Paz Institute for Health Research (IdiPAZ), Spain 0.02
Tel Aviv Sourasky Medical Center, Israel 0.02
Chaim Sheba Medical Center at Tel HaShomer, Israel 0.02
Rabin Medical Center (RMC), TAU, Israel 0.02
Dana-Farber Cancer Institute (DFCI), United States of America (USA) 0.02
New York-Presbyterian Hospital, United States of America (USA) 0.02

Return